Avanos Medical, Inc. to Nominate James Cunniff and William Burke to Board of Directors
Enters into Agreement with Bradley L. RadoffALPHARETTA, Ga., Feb. 26, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading...
Read moreDetails
Health & Fitness
HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting
BOSTON, Feb. 26, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric...
Read moreDetailsViatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
Reports Fourth-Quarter Total Revenues of $3.7B and Full-Year 2025 Total Revenues of $14.3BMeets or Exceeds 2025 Financial Guidance Across All...
Read moreDetailsViatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on February 23, 2026, its Board of...
Read moreDetailsPerrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations
Delivered FY2025 Adj. EPS at the Midpoint of Updated Outlook RangeAdvanced '3-S Plan' with Perrigo Store Brand OTC and Key Brands Gaining Share1,2 in 2025, Despite Soft Category ConsumptionLaunching New Operational Enhancement Program - Expected to Deliver Pre-Tax Annualized...
Read moreDetails
Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3In...
Read moreDetailsImmunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 ––...
Read moreDetailsNuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results
Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA...
Read moreDetailsBrainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for...
Read moreDetails
P-Cure Completes World’s First Conversion of Linear Accelerator Vault into Compact Proton Therapy Center
JERUSALEM, Feb. 26, 2026 /PRNewswire/ -- P-Cure, a leader in compact proton therapy solutions, has announced the successful completion of...
Read moreDetails